Beta
Trial Radar KI
enums.trial_summary.trial_summary_welcome
Eine Studie entspricht den Filterkriterien
Kartenansicht

New Mechanisms of Obesity (NMoO)

Noch nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06768827 (NMoO) ist eine interventionsstudie zur Untersuchung von Obesity and Overweight, Insulinresistenz, Obesity and Obesity-related Medical Conditions und hat den Status noch nicht rekrutierend. Der Start ist für 1. November 2025 geplant, bis 55 Teilnehmer aufgenommen werden. Durchgeführt von Yale University wird der Abschluss für 31. März 2030 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 26. September 2025 aktualisiert.
Kurzbeschreibung
Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.
Ausführliche Beschreibung
Pediatric obesity is a major health burden affecting millions of children and adolescents as it predisposes to the development of cardio-metabolic diseases early in life, such as insulin resistance, fatty liver disease and type 2 diabetes. Investigators have recently completed a series of studies to understand the relationship between the intestinal microbial activity and human metabolism in youth. It was observed that intestinal fermentation, a process through which fermentable carbohydrates are processed by intestinal bacteria, results in a variety of biological responses aimed at protecting the human body from developing obesity and some of its metabolic complications, such as insulin resistance and ectopic fat accumulation. In particular, investigators observed that intestinal fermentation causes 1- a reduction of plasma free fatty acids (FFA), due to the inhibition of adipose tissue lipolysis (ATL); 2- a marked entero-endocrine response to reduce appetite, characterized by an increase in the production of peptide YY (PYY) and glucagon-like peptide1 (GLP-1) and a reduced production of ghrelin. In addition, investigators observed that some intestinal fermentation responses are impaired in youth with obesity and insulin resistance (OIR). In light of this evidence, the current proposal will address: 1- how adipose tissue lipolysis response to intestinal fermentation is affected by insulin resistance; 2- whether changes in ATL, observed when fermentation occurs, are also associated with a reduction of glycerol derived neo-gluconeogenesis; 3- if physical activity may restore the entero-endocrine and adipose tissue response to intestinal fermentation in youth with insulin resistance. This is the first study to test the effect of insulin resistance on the relationship between intestinal microbial metabolic activity and human metabolism (namely adipose tissue lipolysis, gluconeogenesis and entero-endocrine response). The results obtained will provide fundamental insight into how insulin resistance occurring in youth with obesity affects the metabolic response to fermentable carbohydrates. In fact, despite the large body of literature showing an association between intestinal microbial fermentation and human metabolism, how and whether insulin resistance may modulate this association remains unknown.
Offizieller Titel

Pathogenic Mechanisms of Obesity and Its Cardiometabolic Complications

Erkrankungen
Obesity and OverweightInsulinresistenzObesity and Obesity-related Medical Conditions
Weitere Studien-IDs
NCT-Nummer
Studienbeginn (tatsächlich)
2025-11
Zuletzt aktualisiert
2025-09-26
Studienende (vorauss.)
2030-03-31
Geplante Rekrutierung
55
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Noch nicht rekrutierend
Stichwörter
Obesity
Youth
Insulin Resistance
Intestinal Fermentation
Primäres Ziel
Grundlagenforschung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellRemote physical exercise
Lactulose Oral Product
Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Aktives VergleichspräparatControl physical excercise
Lactulose Oral Product
Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)
Changes in adipose tissue lipolysis occurring after colonic fermentation (stimulated by lactulose) will be compared between youth with obesity and insulin resistance (OIR) and with obesity and without insulin resistance (OIS). Lipolysis will be measured by using change in D5-glycerol concentration.
6 hours
CHANGES IN GLUCONEOGENESIS
Gluconeogenesis (GLC) will be measured using change in deuterium oxide concentration after colonic fermentation due to lactulose ingestion and compared between OIS and OIR.
6 hours
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)
Changes in ATL due to colonic fermentation will be measured in two groups of OIR youth. One group will undergo physical activity for 12 weeks and another group will undergo a control intervention. Lipolysis will be measured by using change in D5-glycerol concentration.
Baseline and 12 weeks
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
CHANGES IN PEPTIDE YY (PYY) concentration
Changes in PYY concentration after lactulose intervention will be compared between OIS and OIR.
Baseline and 12 weeks
CHANGES IN GHRELIN concentration
Changes in GHRELIN concentration after lactulose intervention will be compared between OIS and OIR.
Baseline and 12 weeks
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene
Mindestalter
15 Years
Zugelassene Geschlechter
Alle
  • Age 15 to 22 years
  • In puberty (girls and boys: Tanner stage III-V);
  • BMI >85th

  • Pregnancy;
  • endocrinopathies (e.g., Cushing syndrome);
  • substance abuse;
  • medications affecting insulin resistance such as metformin, GLP-1 analogues; -
  • high fibers intake (> 30g/day) as assessed by a 3-day food record.
  • National Institutes of Health (NIH) logoNational Institutes of Health (NIH)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) logoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Zentrale Studienkontakte
Kontakt: NICOLA SANTORO, MD, PhD, 2037852819, [email protected]
1 Studienstandorte in 1 Ländern

Connecticut

Yale University, New Haven, Connecticut, 06520, United States